Viridian Therapeutics, Inc.VRDNNASDAQ
LOADING
|||
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 65.65% |
| Q2 2025 | -15.90% |
| Q1 2025 | -9.01% |
| Q4 2024 | -3.96% |
| Q3 2024 | -18.00% |
| Q2 2024 | -33.89% |
| Q1 2024 | 27.40% |
| Q4 2023 | -40.29% |
| Q3 2023 | 13.44% |
| Q2 2023 | 19.20% |
| Q1 2023 | -48.85% |
| Q4 2022 | -58.40% |
| Q3 2022 | 1.99% |
| Q2 2022 | -14.78% |
| Q1 2022 | 11.24% |
| Q4 2021 | -106.12% |
| Q3 2021 | 21.83% |
| Q2 2021 | 2.69% |
| Q1 2021 | 79.66% |
| Q4 2020 | -1551.66% |
| Q3 2020 | 14.62% |
| Q2 2020 | 20.00% |
| Q1 2020 | 20.50% |
| Q4 2019 | 9.90% |
| Q3 2019 | -26.24% |
| Q2 2019 | 23.50% |
| Q1 2019 | -12.72% |
| Q4 2018 | -14.49% |
| Q3 2018 | -3.41% |
| Q2 2018 | -86.96% |
| Q1 2018 | 27.01% |
| Q4 2017 | -9.46% |
| Q3 2017 | 20.21% |
| Q2 2017 | -4.76% |
| Q1 2017 | -25.31% |
| Q4 2016 | -202.88% |
| Q3 2016 | 26.65% |
| Q2 2016 | 9.10% |
| Q1 2016 | 7.45% |
| Q4 2015 | 5.46% |